Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Danusertib (PHA-739358) 是一种极光激酶抑制剂,能够抑制 Aurora A、Aurora B 和 Aurora C 的活性,IC50值分别为 13、79 和 61 nM。它是一种具有潜在抗肿瘤活性的小分子 3-氨基吡唑衍生物。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 383 | 现货 | ||
2 mg | ¥ 549 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 2,780 | 现货 | ||
50 mg | ¥ 4,130 | 现货 | ||
100 mg | ¥ 5,890 | 现货 | ||
500 mg | ¥ 11,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 953 | 现货 |
产品描述 | Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed. |
靶点活性 | TrkA:31 nM, Aurora A:13 nM, Abl:25 nM, FGFR1:47 nM, RET:31 nM |
体外活性 | Danusertib显著抑制K562细胞的增殖,并在10天的治疗期间抑制肿瘤的生长.给予HL-60异种移植大鼠25 mg/kg Danusertib(b.d.i.v.)导致75%的肿瘤生长被抑制,并且在一只动物中完全消退. |
体内活性 | 在细胞测定中,在用Danusertib处理野生型和p53缺陷型MEF后,野生型细胞在有丝分裂(4N)中停滞,持续48小时,而p53缺陷细胞不会在4N DNA阶段停滞,持续有丝分裂,DNA变为>8N。Danusertib处理导致p53蛋白水平的上升和p21蛋白的增多,已知p53在转录水平上调节p21蛋白。Danusertib抑制其他激酶如FGFR1,Abl,Ret和Trka的活性,IC50分别为47 nM,25 nM,31 nM和31 nM。 |
激酶实验 | Biochemical kinase Assays: The Km values for ATP and the specific substrate are initially determined, and each assay is then run at optimized ATP (2Km) and substrate (5Km) concentrations. This setting enabled direct comparison of IC50 values of Danusertib across the applied kinase selectivity screening panel for the evaluation of the selectivity profile. |
细胞实验 | For short-term expansion assays, 1 × 103 CD34+ cells are plated in triplicates in 96-well plates containing 100 μL of serum-free medium per well supplemented with human stem-cell factor (100 ng/mL), human Flt-3 Ligand (100 ng/mL), human thrombopoietin (50 ng/mL), human interleukin-3 and -6 (IL-3 and IL-6, respectively, both 20 ng/mL), and granulocyte colony-stimulating factor (20 ng/mL) along with Danusertib at the indicated concentrations. After 5 days, an additional 100 μL of cytokine and Danusertib containing medium are added. Cell numbers within each individual well are estimated on days 3, 6, and 9 or on days 3, 6, and 12 for healthy donor samples. (Only for Reference) |
别名 | PHA-739358 |
分子量 | 474.55 |
分子式 | C26H30N6O3 |
CAS No. | 827318-97-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 88 mg/mL (185.4 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1073 mL | 10.5363 mL | 21.0726 mL | 52.6815 mL |
5 mM | 0.4215 mL | 2.1073 mL | 4.2145 mL | 10.5363 mL | |
10 mM | 0.2107 mL | 1.0536 mL | 2.1073 mL | 5.2681 mL | |
20 mM | 0.1054 mL | 0.5268 mL | 1.0536 mL | 2.6341 mL | |
50 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 1.0536 mL | |
100 mM | 0.0211 mL | 0.1054 mL | 0.2107 mL | 0.5268 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Danusertib 827318-97-8 Angiogenesis Apoptosis Autophagy Cell Cycle/Checkpoint Chromatin/Epigenetic Cytoskeletal Signaling Tyrosine Kinase/Adaptors FGFR Trk receptor c-RET Bcr-Abl Aurora Kinase inhibit PHA-739358 PHA 739358 PHA739358 Inhibitor inhibitor